Christopher W. Krueger net worth and biography

Christopher Krueger Biography and Net Worth

Insider of Ventyx Biosciences

Christopher Krueger is the Insider of Ventyx Biosciences.

What is Christopher W. Krueger's net worth?: The estimated net worth of Christopher W. Krueger is at least $3.98 million as of April 2nd, 2024. Krueger owns 284,999 shares of Ventyx Biosciences stock worth more than $3,981,436 as of February 14th. This net worth evaluation does not reflect any other investments that Krueger may own. Learn More about Christopher W. Krueger's net worth.
How do I contact Christopher W. Krueger?: The corporate mailing address for Krueger and other Ventyx Biosciences executives is , , . Ventyx Biosciences can also be reached via phone at 760-593-4832 and via email at [email protected]. Learn More on Christopher W. Krueger's contact information.
Has Christopher W. Krueger been buying or selling shares of Ventyx Biosciences?: Christopher W. Krueger has not been actively trading shares of Ventyx Biosciences during the past quarter. Most recently, Christopher W. Krueger sold 1,651 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $5.40, for a transaction totalling $8,915.40. Following the completion of the sale, the insider now directly owns 284,999 shares of the company's stock, valued at $1,538,994.60. Learn More on Christopher W. Krueger's trading history.
Who are Ventyx Biosciences' active insiders?: Ventyx Biosciences' insider roster includes Sheila Gujrathi (Director), Christopher Krueger (Insider), Raju Mohan (CEO), and John Nuss (Insider). Learn More on Ventyx Biosciences' active insiders.
Are insiders buying or selling shares of Ventyx Biosciences?: During the last year, insiders at the sold shares 2 times. They sold a total of 60,020 shares worth more than $463,354.40. The most recent insider tranaction occured on December, 18th when CEO Raju Mohan sold 47,345 shares worth more than $365,503.40. Insiders at Ventyx Biosciences own 14.5% of the company. Learn More about insider trades at Ventyx Biosciences.
Information on this page was last updated on 12/18/2025.

Christopher W. Krueger Insider Trading History at Ventyx Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2024	Sell	1,651	$5.40	$8,915.40	284,999
10/3/2023	Sell	15,000	$29.98	$449,700.00	276,548
6/5/2023	Sell	15,000	$34.36	$515,400.00	276,548
4/3/2023	Sell	15,000	$32.88	$493,200.00	276,117
12/13/2022	Sell	30,000	$34.46	$1,033,800.00	272,692
12/2/2022	Sell	50,000	$29.01	$1,450,500.00	302,692

Christopher W. Krueger Buying and Selling Activity at Ventyx Biosciences

Ventyx Biosciences Company Overview

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

Today's Range

Now: $13.97

$13.93

$13.97

50 Day Range

MA: $11.63

$7.69

$14.03

2 Week Range

Now: $13.97

$0.78

$25.00

Volume

2,530,427 shs

Average Volume

2,201,694 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25